These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19138400)

  • 1. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.
    Hurkmans CW; Cuijpers JP; Lagerwaard FJ; Widder J; van der Heide UA; Schuring D; Senan S
    Radiat Oncol; 2009 Jan; 4():1. PubMed ID: 19138400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
    Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
    J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Setting up a lung stereotactic body radiotherapy service in a tertiary center in Eastern India: The process, quality assurance, and early experience.
    Shrimali RK; Saha A; Arun B; Prasath S; Nallathambi C; Bhoumik S; Mallick I; Achari RB; Chatterjee S
    J Cancer Res Ther; 2020; 16(4):888-899. PubMed ID: 32930136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients.
    Samson P; Keogan K; Crabtree T; Colditz G; Broderick S; Puri V; Meyers B
    Lung Cancer; 2017 Jan; 103():6-10. PubMed ID: 28024698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer.
    Timmerman R; Galvin J; Michalski J; Straube W; Ibbott G; Martin E; Abdulrahman R; Swann S; Fowler J; Choy H
    Acta Oncol; 2006; 45(7):779-86. PubMed ID: 16982540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.
    Moustakis C; Blanck O; Ebrahimi Tazehmahalleh F; Ka Heng Chan M; Ernst I; Krieger T; Duma MN; Oechsner M; Ganswindt U; Heinz C; Alheit H; Blank H; Nestle U; Wiehle R; Kornhuber C; Ostheimer C; Petersen C; Pollul G; Baus W; Altenstein G; Beckers E; Jurianz K; Sterzing F; Kretschmer M; Seegenschmiedt H; Maass T; Droege S; Wolf U; Schoeffler J; Haverkamp U; Eich HT; Guckenberger M
    Strahlenther Onkol; 2017 Oct; 193(10):780-790. PubMed ID: 28567503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust Optimization of SBRT Planning for Patients With Early Stage Non-Small Cell Lung Cancer.
    Shang H; Pu Y; Wang Y
    Technol Cancer Res Treat; 2020; 19():1533033820916505. PubMed ID: 32314663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403).
    Nishio T; Kunieda E; Shirato H; Ishikura S; Onishi H; Tateoka K; Hiraoka M; Narita Y; Ikeda M; Goka T
    Phys Med Biol; 2006 Nov; 51(21):5409-17. PubMed ID: 17047260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose.
    Schuring D; Hurkmans CW
    Radiat Oncol; 2008 Jul; 3():21. PubMed ID: 18662379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric evaluation of a conformal seven-field coplanar technique for planning lung stereotactic body radiotherapy.
    Richmond N; Green J; Peedell C; Shakespeare D; Walker C
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):e24-30. PubMed ID: 21763114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors.
    Iwata H; Ishikura S; Murai T; Iwabuchi M; Inoue M; Tatewaki K; Ohta S; Yokota N; Shibamoto Y
    Int J Clin Oncol; 2017 Aug; 22(4):706-714. PubMed ID: 28429140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
    Wojcieszynski AP; Hill PM; Rosenberg SA; Hullett CR; Labby ZE; Paliwal B; Geurts MW; Bayliss RA; Bayouth JE; Harari PM; Bassetti MF; Baschnagel AM
    Technol Cancer Res Treat; 2017 Jun; 16(3):366-372. PubMed ID: 28168936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer.
    Xiao Y; Papiez L; Paulus R; Timmerman R; Straube WL; Bosch WR; Michalski J; Galvin JM
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1235-42. PubMed ID: 19251095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
    Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
    Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric comparison of flattened and unflattened beams for stereotactic ablative radiotherapy of stage I non-small cell lung cancer.
    Hrbacek J; Lang S; Graydon SN; Klöck S; Riesterer O
    Med Phys; 2014 Mar; 41(3):031709. PubMed ID: 24593713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey.
    Ramella S; Maranzano E; Frata P; Mantovani C; Lazzari G; Menichelli C; Navarria P; Pergolizzi S; Salvi F
    Tumori; 2012; 98(1):66-78. PubMed ID: 22495704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of three-dimensional image-guided stereotactic localization in the hypofractionated treatment of lung cancer.
    Wang L; Feigenberg S; Chen L; Pasklev K; Ma CC
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):738-47. PubMed ID: 16949768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors.
    Wu J; Li H; Shekhar R; Suntharalingam M; D'Souza W
    Radiother Oncol; 2008 Apr; 87(1):35-43. PubMed ID: 18359529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.